Business NewsNews

DABRA hits 94% success rate in treating PAD

Ra Medical Systems Inc. announced in early March study results that concluded DABRA Laser System achieved 94 percent success rates in patients with peripheral artery disease.

Athar Ansari, MD, director of the California Heart & Vascular Clinic and principal in the study, said DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is fundamentally changing the way he practices medicine.

His study demonstrated a 94 percent success rate treating peripheral artery disease (PAD) by ablating arterial blockages. He presented his findings at this year’s Joint Interventional Meeting in Milan, Italy.

In Dr. Ansari’s study, 292 lesions were treated in 200 patients at his outpatient office-based lab in El Centro, Calif., an area with high diabetes, peripheral artery disease and amputation rates.

“In my experience, DABRA delivers results rapidly and safely, even in challenging cases,” Dr. Ansari said. “DABRA can treat all types of plaques in arteries above and below the knee. Patients are discharged in two to three hours, allowing them to quickly return to their daily lives.

“Most importantly, DABRA meets the need for safe, high-quality tools in smaller-scale settings, including office-based labs, allowing me to spare patients from hospital stays and reduce costs.”

DABRA, which launched in 2017 for the endovascular treatment of blockages resulting from lower extremity vascular disease, is a novel, minimally invasive excimer laser system that non-thermally, photochemically ablates channels in vascular blockages. Unlike many treatments for PAD that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma, according to Ra Medical Systems CEO Dean Irwin.

“We believe Dr. Ansari’s study and experience are further evidence that DABRA benefits patients, physicians, and the healthcare system as a whole,” Irwin said. “We are delivering on our mission to provide physicians a better treatment to save limbs and lives in the U.S. and around the world.” VTN



Previous post

FDA issues ‘concerning signal’ on paclitaxel-coated devices

Next post

Healogics adds vein ablation to wound care treatments

Larry Storer

Larry Storer

Larry Storer has been editor of Vein Therapy News for 10 years. He has edited computer, shelter and medical publications at Publications & Communications LP for 30 years. He was also a corporate vice president and editorial director before retiring. Larry graduated from Baylor University with a BA in journalism and an MA in communications; and from Lamar University with a MED in school administration. He taught beginning and advanced reporting, beginning and advanced editing and editorial writing at Baylor University. Larry was a reporter, and city and news editor of the Beaumont Journal, and opinion editor at the Beaumont Enterprise and Beaumont Enterprise-Journal. He was also the founding managing editor of the Yuba City (California) Daily Independent-Herald.